3Sbio Inc.

3Sbio Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

关于三生制药集团 三生制药集团是一家集研发、生产和销售为一体的生物制药领军企业,致力于以高品质的药品提高患者生存质量,为人类健康造福。目前,集团拥有80余项国家发明专利授权,30余种上市产品,覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。集团拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心,共有25种在研产品,其中16种作为国家一类新药正在研发,并拥有符合GMP标准的6大生产基地。未来,三生制药集团将继续秉持“珍爱生命、关注生存、创造生活”的理念,全力打造全球领先的中国生物制药企业。 About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world's leading bio-pharmaceutical company in China.

Company Details

Employees
388
Founded
-
Address
No.399 Libing Road Zhangjiang High-Tech Park, Shanghai,shanghai 201203,china
Phone
862425386000
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
3sbio.com
HQ
Shanghai , Shanghai
Looking for a particular 3Sbio Inc. employee's phone or email?

3sbio Inc. Questions

News

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers - Pharmaceutical Executive

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers Pharmaceutical Executive

Pfizer buys into PD-1/VEGF competition with 3SBio deal - BioPharma Dive

Pfizer buys into PD-1/VEGF competition with 3SBio deal BioPharma Dive

Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio - Oncodaily

Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio Oncodaily

Pfizer and 3SBio conclude licensing deal for SSGJ-707 - Pharmaceutical Technology

Pfizer and 3SBio conclude licensing deal for SSGJ-707 Pharmaceutical Technology

ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Pfizer Enters into Exclusive Licensing Agreement with 3SBio - Business Wire

Pfizer Enters into Exclusive Licensing Agreement with 3SBio Business Wire

Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio - Fierce Pharma

Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio Fierce Pharma

Pfizer Licenses 3SBio Cancer Drug For Record $1.2 Billion - Bloomberg

Pfizer Licenses 3SBio Cancer Drug For Record $1.2 Billion Bloomberg

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China Investopedia

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race - BioWorld MedTech

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race BioWorld MedTech

Han Kun advises 3SBio in landmark Pfizer licensing deal - Law.asia

Han Kun advises 3SBio in landmark Pfizer licensing deal Law.asia

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake - Reuters

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake Reuters

Pfizer enters into exclusive licensing agreement worth $4.8 B with China's 3SBio - BioSpectrum Asia

Pfizer enters into exclusive licensing agreement worth $4.8 B with China's 3SBio BioSpectrum Asia

3SBio hits the big time with $6 billion cancer drug deal - thebambooworks.com

3SBio hits the big time with $6 billion cancer drug deal thebambooworks.com

Pfizer Completes Licensing Agreement with 3SBio - Business Wire

Pfizer Completes Licensing Agreement with 3SBio Business Wire

Pfizer completes licensing agreement with 3SBio - Express Pharma

Pfizer completes licensing agreement with 3SBio Express Pharma

Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody - BioWorld MedTech

Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody BioWorld MedTech

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% - PR Newswire

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% PR Newswire

Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc. - Yahoo Finance

Pfizer Inc. (PFE) Finalizes Global Licensing Agreement with 3sbio, Inc. Yahoo Finance

Pfizer signs global licensing deal with 3SBio for bispecific antibody - Pharmaceutical Technology

Pfizer signs global licensing deal with 3SBio for bispecific antibody Pharmaceutical Technology

Arvinas and 3SBio hope to do better | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Arvinas and 3SBio hope to do better | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced - PR Newswire

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced PR Newswire

Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy - MedCity News

Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy MedCity News

Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF - BioPharm International

Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF BioPharm International

Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn - PMLiVE

Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn PMLiVE

3SBio Partners with Pfizer for Global Licensing of Oncology Antibody - TipRanks

3SBio Partners with Pfizer for Global Licensing of Oncology Antibody TipRanks

Pfizer Thinks Bigger With 3SBio Deal (NYSE:PFE) - Seeking Alpha

Pfizer Thinks Bigger With 3SBio Deal (NYSE:PFE) Seeking Alpha

Chinese biotech firm secures Pfizer deal despite trade tensions - South China Morning Post

Chinese biotech firm secures Pfizer deal despite trade tensions South China Morning Post

Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug - The Economic Times

Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug The Economic Times

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth - PR Newswire

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth PR Newswire

3Sbio licenses out global rights of PD-1 inhibitor to Syncromune - BioWorld MedTech

3Sbio licenses out global rights of PD-1 inhibitor to Syncromune BioWorld MedTech

TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China - GlobeNewswire

TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China GlobeNewswire

3SBio and Pfizer Finalize License Agreement and Share Subscription - TipRanks

3SBio and Pfizer Finalize License Agreement and Share Subscription TipRanks

China's 3SBio surges over 37% after $6B Pfizer deal - breakingthenews.net

China's 3SBio surges over 37% after $6B Pfizer deal breakingthenews.net

3SBio enters licensing deal for antibody-drug conjugate ALT-P7 - Drug Target Review

3SBio enters licensing deal for antibody-drug conjugate ALT-P7 Drug Target Review

Pfizer signs licensing deal worth about US$6 billion with China's 3SBio for cancer drug - The Standard (HK)

Pfizer signs licensing deal worth about US$6 billion with China's 3SBio for cancer drug The Standard (HK)

3SBio Q4 11 Earnings Conference Call At 8:00 AM ET - RTTNews

3SBio Q4 11 Earnings Conference Call At 8:00 AM ET RTTNews

AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China - Fierce Pharma

AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China Fierce Pharma

3SBio & Selecta To Develop Non-Immunogenic Gout Drug - Asian Scientist Magazine

3SBio & Selecta To Develop Non-Immunogenic Gout Drug Asian Scientist Magazine

3SBio: Firm hold over biopharma - Forbes India

3SBio: Firm hold over biopharma Forbes India

3SBio appoints Kevin Xiao Weihong as new COO - BioSpectrum Asia

3SBio appoints Kevin Xiao Weihong as new COO BioSpectrum Asia

Top 3Sbio Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant